PDF(Pubmed)
Abstract：
BACKGROUND: Gout is a common and complex form of immunoreactive arthritis based on hyperuricemia, while the symptoms would turn to remission or even got worse. So, it is hard to early identify whether an asymptomatic hyperuricemia (AHU) patient will be susceptible to get acute gout attack and it is also hard to predict the process of gout remission to flare. Here, we report that the plasma proteins profile can distinguish among acute gout (AG), remission of gout (RG), AHU patients, and healthy controls.
METHODS: We established an isobaric tags for relative and absolute quantification (iTRAQ) and parallel reaction monitoring (PRM) based method to measure the plasma proteins for AG group (n = 8), RG group (n = 7), AHU group (n = 7) and healthy controls (n = 8).
RESULTS: Eleven differentially expressed proteins such as Histone H2A, Histone H2B, Thrombospondin-1 (THBS1), Myeloperoxidase (MPO), Complement C2, Complement component C8 beta chain (C8B), Alpha-1-acid glycoprotein 1 (ORM1), Inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4), Carbonic anhydrase 1 (CA1), Serum albumin (ALB) and Multimerin-1 (MMRN1) were identified. Histone H2A, Histone H2B and THBS1 might be the strongest influential regulator to maintain the balance and stability of the gout process. The complement and coagulation cascades is one of the main functional pathways in the mechanism of gout process.
CONCLUSIONS: Histone H2A, Histone H2B and THBS1 are potential candidate genes for novel biomarkers in discriminating gout attack from AHU or RG, providing new theoretical insights for the prognosis, treatment, and management of gout process.
BACKGROUND: This study is not a clinical trial.
METHODS: We established an isobaric tags for relative and absolute quantification (iTRAQ) and parallel reaction monitoring (PRM) based method to measure the plasma proteins for AG group (n = 8), RG group (n = 7), AHU group (n = 7) and healthy controls (n = 8).
RESULTS: Eleven differentially expressed proteins such as Histone H2A, Histone H2B, Thrombospondin-1 (THBS1), Myeloperoxidase (MPO), Complement C2, Complement component C8 beta chain (C8B), Alpha-1-acid glycoprotein 1 (ORM1), Inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4), Carbonic anhydrase 1 (CA1), Serum albumin (ALB) and Multimerin-1 (MMRN1) were identified. Histone H2A, Histone H2B and THBS1 might be the strongest influential regulator to maintain the balance and stability of the gout process. The complement and coagulation cascades is one of the main functional pathways in the mechanism of gout process.
CONCLUSIONS: Histone H2A, Histone H2B and THBS1 are potential candidate genes for novel biomarkers in discriminating gout attack from AHU or RG, providing new theoretical insights for the prognosis, treatment, and management of gout process.
BACKGROUND: This study is not a clinical trial.
摘要：
背景：痛风是基于高尿酸血症的免疫反应性关节炎的常见且复杂形式，而症状会缓解甚至恶化。所以,很难早期确定无症状高尿酸血症（AHU）患者是否容易急性痛风发作，也很难预测痛风缓解至发作的过程。这里,我们报道血浆蛋白谱可以区分急性痛风（AG），痛风缓解（RG），AHU患者,和健康的控制。
方法：我们建立了基于相对和绝对定量（iTRAQ）和平行反应监测（PRM）的同量异位标签，以测量AG组（n=8）的血浆蛋白，RG组（n=7），AHU组(n=7)和健康对照(n=8)。
结果：11种差异表达蛋白，如组蛋白H2A，组蛋白H2B,血小板反应蛋白-1(THBS1),髓过氧化物酶(MPO),补体C2，补体组分C8β链（C8B），α-1-酸性糖蛋白1（ORM1），α-胰蛋白酶抑制剂重链H4(ITIH4),碳酸酐酶1(CA1),鉴定血清白蛋白(ALB)和Multimerin-1(MMRN1)。组蛋白H2A,组蛋白H2B和THBS1可能是维持痛风过程平衡和稳定的最强调节因子。补体和凝血级联反应是痛风发病机制中的主要功能通路之一。
结论：组蛋白H2A，组蛋白H2B和THBS1是区分痛风发作与AHU或RG的新型生物标志物的潜在候选基因，为预后提供新的理论见解，治疗,和痛风过程的管理。
背景：本研究不是临床试验。
方法：我们建立了基于相对和绝对定量（iTRAQ）和平行反应监测（PRM）的同量异位标签，以测量AG组（n=8）的血浆蛋白，RG组（n=7），AHU组(n=7)和健康对照(n=8)。
结果：11种差异表达蛋白，如组蛋白H2A，组蛋白H2B,血小板反应蛋白-1(THBS1),髓过氧化物酶(MPO),补体C2，补体组分C8β链（C8B），α-1-酸性糖蛋白1（ORM1），α-胰蛋白酶抑制剂重链H4(ITIH4),碳酸酐酶1(CA1),鉴定血清白蛋白(ALB)和Multimerin-1(MMRN1)。组蛋白H2A,组蛋白H2B和THBS1可能是维持痛风过程平衡和稳定的最强调节因子。补体和凝血级联反应是痛风发病机制中的主要功能通路之一。
结论：组蛋白H2A，组蛋白H2B和THBS1是区分痛风发作与AHU或RG的新型生物标志物的潜在候选基因，为预后提供新的理论见解，治疗,和痛风过程的管理。
背景：本研究不是临床试验。
